Synonyms: LY2484595
Compound class:
Synthetic organic
Comment: Evacetrapib is a cholesterylester transfer protein (CETP) inhibitor [1]. CETP was considered as a target for prevention of dyslipidemia and resucing cardiovascular mortality, with CETP inhibitors proposed as a direct route to raise HDL.
Clinical trial results for a number of CETP inhibitors have failed to show clinical benefit. Failed candidates include evacetrapib, anacetrapib, torcetrapib, and dalcetrapib [3]. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Fernandez MC, Escribano A, Mateo AI, Parthasarathy S, Martin de la Nava EM, Wang X, Cockerham SL, Beyer TP, Schmidt RJ, Cao G et al.. (2012)
Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors. Bioorg Med Chem Lett, 22 (9): 3056-62. [PMID:22497761] |
2. Rader DJ, deGoma EM. (2014)
Future of cholesteryl ester transfer protein inhibitors. Annu Rev Med, 65: 385-403. [PMID:24422575] |
3. Ready JM. (2021)
Toward a Best-in-Class Inhibitor of Cholesteryl Ester Transfer Protein (CETP). J Med Chem, 64 (18): 13212-13214. [PMID:34498872] |
4. Sahebkar A, Chew GT, Watts GF. (2014)
Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res, 56: 47-66. [PMID:25083925] |